argenx: The Sjögren's Selloff Looks Overdone (NASDAQ:ARGX)
· seekingalpha.com
argenx shares fell after halting its Phase 3 Sjögren's trial, but the selloff appears to overstate the lost opportunity. Read more on ARGX stock here.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions...